Announcing the U.S. and Korea release of NeuroMatch®. Learn more:

United States Korea

Press Releases

LVIS NeuroMatch® Software Successfully Launched in 10 South Korean Hospitals

Over the years, researchers have made significant leaps in how we identify, treat, and manage neurological disorders – but in the past decade, these leaps have accelerated exponentially. At LVIS Corp, we’re driven by a passion for innovation and solving complex neurological challenges. Our team is in the midst of redefining the landscape of diagnosis ... Read more
NeuroMatch software user

Announcing the NeuroMatch Ambassador Program: Your Expertise, Our Innovation

We are excited to extend a special invitation to select medical professionals for the private beta launch of our latest technology.
ACNS Orlando feature image

LVIS Corporation Introduces NeuroMatch® at 2024 American Clinical Neurophysiology Society Meeting

LVIS Corporation, a leading innovator in healthcare technology, is pleased to announce its participation in the upcoming 2024 American Clinical Neurophysiology Society (ACNS) Meeting in Orlando, Florida, from February 29 to March 2, 2024.
AES Orlando feature image

LVIS Corporation to Showcase Innovative Epilepsy Solution at the 2023 American Epilepsy Society Meeting

LVIS Corporation, a leading innovator in healthcare technology, is thrilled to announce its participation in the upcoming 2023 American Epilepsy Society (AES) Meeting in Orlando, Florida, from December 1 to 5.

We have an international team with our headquarters located in Palo Alto, California, USA, and offices in Gangnam, Seoul, Korea, and Daegu, Korea.

Palo Alto, California
Gangnam, Seoul, Korea
Daegu, Korea

© 2025 LVIS Corporation. All Rights Reserved.

Terms Of Service
Privacy Policy

LVIS has obtained regulatory clearance for NeuroMatch in the United States and Korea.
NeuroMatch United States FDA Clearance #: K241390
NeuroMatch Korea MFDS Clearance #: License number 23-4685
Certain features shown are not yet cleared in the United States.